PulmoBioMed, a pioneering company in the field of breath sampling technology, has successfully raised £1.4 million in a funding round, marking a significant milestone for the company.
The funding round, spearheaded by the North East Venture Fund managed by Mercia Ventures, saw participation from notable entities such as Northumbria University, SFC Capital, and private investors from the USA, EU, and UK.
In addition to this funding, PulmoBioMed also secured a £700,000 grant from Innovate UK, reinforcing the company’s commitment to advancing its groundbreaking technology.
Expansion Plans and Funding Utilization:
The infusion of capital is earmarked for crucial developments in PulmoBioMed’s operations.
The company aims to channel the funds towards refining its manufacturing process, scaling up production, and obtaining regulatory approval for its product in the lucrative US market.
Furthermore, PulmoBioMed envisions a strategic move from its current university-based setup to new premises in Newcastle city centre.
This expansion initiative aligns with the company’s mission to create seven new jobs in the upcoming year, contributing to the growth of the local economy.
Revolutionizing Respiratory Care:
PulmoBioMed, under the leadership of CEO and Founder Sterghios Moschos, is at the forefront of revolutionizing respiratory diagnostics.
The company’s flagship product, the PBM-HALE handheld device, introduces a non-invasive approach to obtaining fluid samples from the lung, eliminating contamination from fluids in the mouth.
The device captures breath during exhalation, separating aerosol droplets from the mouth and those originating from the deep lung.
Clinical studies have demonstrated the efficacy of PBM-HALE in providing uncontaminated deep lung samples within a mere two minutes.
This breakthrough technology has proven instrumental in detecting and quantifying lung infections and inflammation, achieving a 100% success rate in symptomatic cases.
Addressing Critical Healthcare Challenges:
Sterghios Moschos emphasized PulmoBioMed’s origin during the pandemic, highlighting the pressing need for reliable breath-based diagnostics.
He articulated the company’s success in overcoming fundamental challenges, enabling quick and non-invasive deep lung sampling with minimal training.
With more than 300 million asthma patients facing delayed diagnoses and millions hospitalized annually due to pneumonias challenging to diagnose through conventional tests, PulmoBioMed’s PBM-HALE holds immense promise in transforming respiratory care.
By empowering clinicians to better understand their patients’ diseases and select effective treatments, PulmoBioMed aims to make a lasting impact on respiratory healthcare.
PulmoBioMed’s recent funding success underscores the growing recognition and support for innovative solutions in respiratory diagnostics.
With strategic plans for expansion, technological advancements, and a commitment to addressing critical healthcare challenges, PulmoBioMed is poised to contribute significantly to the evolution of respiratory care.Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn